Kuecept Ltd.

Hertfordshire, United Kingdom

Kuecept Ltd.

Hertfordshire, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.2-2 | Award Amount: 13.07M | Year: 2014

Increase in antibiotic resistance is a global concern worldwide. The project NAREBs main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients. NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA. Specific objectives to achieve the main goal are: (i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric); (ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials; (iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging; (iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration) (v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations; (vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations. The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.


Grainger C.I.,King's College London | Saunders M.,Kuecept Ltd | Buttini F.,University of Parma | Telford R.,University of Bradford | And 4 more authors.
Molecular Pharmaceutics | Year: 2012

Determining bioequivalence for solution pressurized metered dose inhalers (pMDI) is difficult because the critical characteristics of such products are poorly defined. The aim of this study was to elucidate the non-aerodynamic properties of the emitted aerosol particles from two solution pMDI products that determine their biopharmaceutical differences after deposition. Novel particle capture and analysis techniques were employed to characterize the physicochemical and biopharmaceutical properties of two beclomethasone dipropionate (BDP) products: QVAR and Sanasthmax. The BDP particles emitted from the Sanasthmax inhaler were discernibly different those emitted from QVAR in terms of size (50% larger, less porous), solid state (less crystalline) and dissolution (20-fold slower). When deposited onto the surface of respiratory epithelial cell layers, QVAR delivered ∼50% more BDP across the cell layer in 60 min than Sanasthmax. Biopharmaceutical performance was not attributable to individual particle properties as these were manifold with summative and/or competing effects. The cell culture dissolution - absorption model revealed the net effect of the particle formed on drug disposition and was predictive of human systemic absorption of BDP delivered by the test inhalers. This illustrates the potential of the technique to detect the effect of formulation on the performance of aerosolized particles and contribute to assessment of bioequivalence. © 2012 American Chemical Society.


Vogt F.G.,Glaxosmithkline | Williams G.R.,Glaxosmithkline | Williams G.R.,Rigaku Corporation | Johnson M.N.,Glaxosmithkline | And 2 more authors.
Crystal Growth and Design | Year: 2013

Two polymorphic forms of ethyl 3-{3-[((2R)-3-{[2-(2,3-dihydro-1H-inden-2- yl)-1,1-dimethylethyl]amino}-2-hydroxypropyl)oxy]-4,5-difluorophenyl} propanoate hydrochloride, an investigational pharmaceutical compound, are characterized using spectroscopic and diffractometric techniques. These polymorphic forms exhibit very similar spectra and diffraction patterns and present challenges for analytical and physical characterization techniques. Capillary powder X-ray diffraction (PXRD) patterns for the two forms show minor but distinct differences. A single crystal X-ray diffraction structure for one of the forms was obtained. The unit cell of the other form was obtained by PXRD indexing. Detailed solid-state nuclear magnetic resonance (SSNMR) studies observing the 1H, 13C, 15N, 19F, and 35Cl nuclei are performed to characterize the subtle structural differences between the two forms. Molecular spectroscopic methods including infrared, Raman, UV-visible, and fluorescence spectroscopy are also applied. The combined results, particularly the results obtained from X-ray diffraction analysis, 13C, 15N, and 35Cl SSNMR, and fluorescence spectroscopy, are consistent with the more thermodynamically stable form having a structure that is an extended, perturbed superstructure of the less stable form. © 2013 American Chemical Society.


Buanz A.B.M.,University of London | Saunders M.H.,Kuecept Ltd. | Basit A.W.,University of London | Basit A.W.,Kuecept Ltd. | Gaisford S.,University of London
Pharmaceutical Research | Year: 2011

Purpose: To evaluate the use of thermal ink-jetting as a method for dosing drugs onto oral films. Methods: A Hewlett-Packard printer cartridge was modified so that aqueous drug solutions replaced the ink. The performance of the printer as a function of print solution viscosity and surface tension was determined; viscosities between 1.1 and 1.5 mm 2 s -1 were found to be optimal, while surface tension did not affect deposition. A calibration curve for salbutamol sulphate was prepared, which demonstrated drug deposition onto an acetate film varied linearly with concentration (r 2∈=∈0. 9992). The printer was then used to deposit salbutamol sulphate onto an oral film made of potato starch. Results: It was found that when doses were deposited in a single pass under the print head, then the measured dose was in good agreement with the theoretical dose. With multiple passes the measured dose was always significantly less than the theoretical dose. It is proposed that the losses arise from erosion of the printed layer by shearing forces during paper handling. The losses were predictable, and the variance in dose deposited was always less than the BP limits for tablet and oral syrup salbutamol sulphate preparations. Conclusions: TIJ printing offers a rapid method for extemporaneous preparation of personalized-dose medicines. © 2011 Springer Science+Business Media, LLC.


Trademark
KUECEPT Ltd | Date: 2012-04-24

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders. Pharmaceutical drug development services; Pharmaceutical research and development.


Trademark
KUECEPT Ltd | Date: 2012-04-24

Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals. Pharmaceutical drug development services; Pharmaceutical research services.

Loading Kuecept Ltd. collaborators
Loading Kuecept Ltd. collaborators